688687.SH
凯因科技
SSE · Healthcare · Biotechnology · CN
CNY 18.05
−0.72%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.3B | 1.3B | 1.2B | 1.4B | 1.2B |
| Cost of Revenue | 252.1M | 235.7M | 223.0M | 232.3M | 155.4M |
| Gross Profit | 1.0B | 1.1B | 1.0B | 1.2B | 1.0B |
| Operating Expenses | |||||
| R&D Expense | 143.4M | 140.9M | 138.2M | 134.2M | 114.2M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 140.0M | 128.1M | 114.9M | 102.9M | 137.2M |
| Selling & Marketing Expense | 606.1M | 629.3M | 597.5M | 793.4M | 716.0M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 903.2M | 908.3M | 842.8M | 1.0B | 954.1M |
| Cost and Expenses | 1.2B | 1.1B | 1.1B | 1.3B | 1.1B |
| Operating Income (EBIT) | 41.8M | 67.4M | 193.0M | 170.8M | 106.5M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 30.1M | 53.7M | 176.8M | 146.2M | 97.7M |
| Income Tax Expense | 10.4M | 13.5M | 17.7M | 9.0M | 17.1M |
| Bottom Line | |||||
| Net Income | 11.1M | 30.6M | 142.4M | 116.5M | 83.4M |
| Earnings from Cont. Ops | 19.7M | 40.3M | 159.2M | 137.3M | 80.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 11.1M | 30.6M | 142.4M | 116.5M | 83.4M |
| Per Share | |||||
| Basic EPS | CN¥0.07 | CN¥0.18 | CN¥0.85 | CN¥0.70 | CN¥0.49 |
| Diluted EPS | CN¥0.07 | CN¥0.18 | CN¥0.85 | CN¥0.70 | CN¥0.49 |
| Revenue Per Share | CN¥8.45 | CN¥7.77 | CN¥7.35 | CN¥8.48 | CN¥6.81 |
| Shares | |||||
| Basic Shares Outstanding | 153.4M | 170.0M | 167.5M | 166.5M | 170.2M |
| Diluted Shares Outstanding | 153.4M | 170.0M | 167.5M | 166.5M | 170.2M |
| Profitability Metrics | |||||
| EBITDA | — | 120.6M | 236.4M | 209.5M | 143.5M |
| D&A | — | 53.3M | 43.4M | 38.6M | 37.0M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026